Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249350 | 0.84 | KMT2A (0.38) | CHRNA7HTR3ACHRNB4CHRNA3KMT2A | |
| SCHEMBL18291571 | 0.81 | CHRNA7 (0.41) | CHRNA7HTR3ACHRNB4CHRNA3KMT2A | |
| SCHEMBL19001109 | 0.80 | KMT2A (0.41) | CHRNA7HTR3ACHRNB4CHRNA3KMT2A | |
| SCHEMBL19001244 | 0.80 | KMT2A (0.41) | CHRNA7HTR3ACHRNB4CHRNA3KMT2A | |
| SCHEMBL20249344 | 0.77 | KMT2A (0.36) | CHRNA7HTR3ACHRNB4CHRNA3KMT2A | |
| SCHEMBL20255570 | 0.76 | CHRNA7 (0.37) | CHRNA7HTR3ACHRNB4CHRNA3KMT2A | |
| SCHEMBL20249356 | 0.76 | TRPV1 (0.42) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL20249359 | 0.76 | TRPV1 (0.42) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL20249165 | 0.76 | TRPV1 (0.42) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL20255397 | 0.75 | CXCR3 (0.33) | CHRNA7HTR3ACHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CHRNA7 4757/4885HTR3A 2802/4885CHRNB4 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.